Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. (Nasdaq: NOVT) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs. This SEC filings page brings together those disclosures so investors can review the company’s regulatory record in one place.
Among the most frequently referenced filings are current reports on Form 8-K, where Novanta announces quarterly financial results, provides non-GAAP metrics such as Adjusted EBITDA and Adjusted Diluted EPS, and discloses material events. Recent 8-K filings have covered results for specific fiscal quarters, revisions to financial guidance, changes in Board composition, and details of share repurchase authorizations.
Filings also document capital markets and financing transactions, including the underwriting agreement and terms of Novanta’s tangible equity units offering, which combines prepaid stock purchase contracts with senior amortizing notes due 2028. Related 8-Ks describe settlement mechanics, interest and installment payments, and the listing of the units under the symbol NOVTU. Other filings outline the terms of the company’s senior credit facilities under its Fourth Amended and Restated Credit Agreement and subsequent amendments, including leverage and coverage covenants.
Through this page, users can access Novanta’s 10-K annual reports and 10-Q quarterly reports (when filed), as well as Forms 4 and other ownership-related filings, via real-time updates from EDGAR. AI-powered summaries help explain complex sections, highlight key changes from prior periods, and clarify the implications of items such as guidance revisions, credit agreement provisions, and share repurchase programs.
Whether reviewing earnings-related disclosures, tracking capital structure developments, or examining governance and compensation information, this filings hub provides a structured entry point into Novanta’s SEC reporting history.
Novanta Inc. reports on its 2025 performance as a global supplier of precision technologies for medical and advanced industrial OEMs. For the year ended December 31, 2025, Automation Enabling Technologies generated revenue of $500.8 million with a gross profit margin of 47.8% and operating profit of $114.5 million, while Medical Solutions delivered revenue of $479.8 million with a 41.6% gross profit margin and operating profit of $51.2 million.
Medical end markets represented about 53% of revenue and advanced industrial about 47%. Backlog was approximately $481.2 million as of December 31, 2025. The company strengthened its balance sheet by issuing 12,650,000 6.50% tangible equity units at $50.00 per unit, recording net proceeds of $613.1 million, and by entering a new $1.0 billion credit facility maturing in June 2030. Novanta also acquired Keonn Technologies for a total purchase price of $75.1 million, expanding its RFID capabilities within the Medical Solutions segment. As of February 16, 2026, Novanta had 35,683,769 common shares outstanding and non‑affiliate market value of $3.50 billion based on June 27, 2025 pricing.
Novanta Inc. reported steady growth for the fourth quarter and full year 2025 while laying out an ambitious 2026 outlook. Fourth quarter 2025 revenue reached $258.3 million, up 8.5% year over year, with GAAP diluted EPS of $0.45 versus $0.46 and Adjusted diluted EPS rising 20% to $0.91. Adjusted EBITDA grew 17% to $60.7 million, supported by a 25% increase in customer bookings and a book-to-bill of 1.11x.
For full year 2025, revenue was $980.6 million, up 3.3%. GAAP diluted EPS declined to $1.47 from $1.77, but Adjusted diluted EPS improved 6.8% to $3.29 and Adjusted EBITDA increased to $221.0 million. Operating cash flow fell to $64.1 million from $158.5 million, mainly due to higher working capital from regionalizing manufacturing.
Novanta ended 2025 with $380.9 million of cash and $250.8 million of total debt, resulting in Net Debt of $(121.3) million. For 2026, the company guides GAAP revenue to $1,030–$1,050 million, Adjusted EBITDA to $245–$250 million and Adjusted diluted EPS to $3.50–$3.65, with operating cash flow of $145–$185 million, and expects mid‑single‑digit organic growth.
Novanta Inc. Co-Chief Operating Officer John Lesica reported equity award activity involving restricted stock units and common shares. He exercised or converted 1,388 restricted stock units into 1,388 common shares, then disposed of 445 common shares at $145.63 per share to cover tax obligations, leaving 943 common shares directly owned after these transactions. Each restricted stock unit represents one Novanta common share and vests in three equal installments on February 18, 2026, February 18, 2027 and February 18, 2028.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported an open‑market sale of 7,500 shares of common stock on February 10, 2026 at a weighted‑average price of $145.04 per share. The sale was made under a pre‑established Rule 10b5‑1 trading plan adopted on September 11, 2025.
Following this transaction, Glastra beneficially owns 57,367 Novanta shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust, for which his spouse serves as trustee.
Novanta, Inc. has a new Rule 144 notice covering a planned sale of 7,500 shares of its common stock. The shares are to be sold through Merrill Private Wealth Management on NASDAQ, with an aggregate market value of 1087500 and 35775123 shares outstanding.
The shares to be sold were acquired as restricted stock units from Novanta, Inc. on 02/24/2022 (1084 shares), 01/03/2023 (4679 shares), and 01/02/2025 (1737 shares), all as equity compensation. A separate table shows that Matthijs Glastra has sold 323, 6177, 7500, and 6500 common shares in the past 3 months for gross proceeds of 41990, 803010, 1050000, and 877500.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported selling a total of 6,500 shares of Novanta common stock on February 2, 2026. The sales were executed in several trades at weighted-average prices between $134.52 and $137.38 per share.
The transactions were made under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which the reporting person’s spouse is a trustee. Following these sales, Glastra directly held 64,867 shares and indirectly held 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust.
Matthijs Glastra filed a notice to sell 6,500 shares of Novanta, Inc. common stock under Rule 144. The shares have an aggregate market value of $878,461, are listed on NASDAQ, and the approximate sale date is 02/02/2026, using Merrill Private Wealth Management as broker.
The filing shows these shares relate to restricted stock units granted as equity compensation on 02/24/2023, 02/26/2024, and 01/02/2025. It also lists recent sales of Novanta common stock by the same person during the past three months, including transactions on 01/08/2026, 01/09/2026, and 01/21/2026 with disclosed gross proceeds.
Novanta Inc.'s Chief Financial Officer Robert Buckley reported an option exercise and share sale in company stock. On 01/21/2026, he exercised a stock option for 1,423 shares of common stock at an exercise price of $14.13 per share and then sold 1,423 shares of common stock at a weighted-average price of $140.1435 per share under transaction code "S." The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025.
Following these transactions, Buckley directly held 91,034 shares of Novanta common stock and had 11,380 stock options remaining. He also had indirect beneficial ownership of 36,219 shares of common stock held through the Buckley Family Irrevocable Trust.
Novanta Inc. disclosed that a trust associated with Chief Executive Officer and director Matthijs Glastra sold common stock under a pre-established trading plan. On January 21, 2026, the entity sold 7,500 shares of Novanta common stock at $140 per share in an open-market transaction. After this sale, Glastra remained beneficial owner of 71,367 shares held directly, and 54,382 shares held indirectly through the Matthijs Glastra 2021 Irrevocable Trust. The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which the reporting person’s spouse is a trustee.
The holder of NOVT common stock has filed a Rule 144 notice to sell 43,920 shares. The planned sale is to be executed through J.P. Morgan Securities LLC on Nasdaq, with an approximate sale date of 01/21/2026. The filing shows these shares were acquired through a mix of stock option exercise on 01/21/2026 and multiple compensation awards from the issuer between 2021 and 2024. The number of shares of the same class outstanding is listed as 35,775,123; this is a baseline figure, not the amount being sold.